Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death

Biochemical Pharmacology

Volumn 88, Issue 2, 2014, Pages 178-188

  Kim, Seog Young ^a   Song, Xinxin ^a   Zhang, Lin ^a   Bartlett, David L ^a   Lee, Yong J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bcl xL; Beclin 1; Bortezomib; Mitochondria dependent pathway; Oxaliplatin

Indexed keywords

BECLIN 1; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL XL; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL STRAIN HCT116; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

BCL-XL; BECLIN-1; BORTEZOMIB; MITOCHONDRIA-DEPENDENT PATHWAY; OXALIPLATIN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BCL-X PROTEIN; BORONIC ACIDS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HCT116 CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; PYRAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895545382     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.027     Document Type: Article

References (51)

1. American Cancer Society Cancer facts & figures 2013 2013 American Cancer Society
2. J.S. Macdonald, S.R. Smalley, J. Benedetti, S.A. Hundahl, N.C. Estes, and G.N. Stemmermann et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725 730
3. M.L. Rothenberg, N.J. Meropol, E.A. Poplin, E. Van Cutsem, and S. Wadler Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 18 2001 3801 3807
4. R.K. Amaravadi, J. Lippincott-Schwartz, X.M. Yin, W.A. Weiss, N. Takebe, and W. Timmer et al. Principles and current strategies for targeting autophagy for cancer treatment Clin Cancer Res 17 2011 654 666
5. N. Chen, and V. Karantza Autophagy as a therapeutic target in cancer Cancer Biol Ther 11 2011 157 168
6. J.P. Waters, J.S. Pober, and J.R. Bradley Tumour necrosis factor and cancer J Pathol 230 2013 241 248
7. Y. Xu, H. Yu, H. Qin, J. Kang, C. Yu, and J. Zhong et al. Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervicalcancer cells Cancer Lett 314 2012 232 243
8. M. Djavaheri-Mergny, M.C. Maiuri, and G. Kroemer Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1 Oncogene 29 2010 1717 1719
9. W. Hou, J. Han, C. Lu, L.A. Goldstein, and H. Rabinowich Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis Autophagy 6 2010 891 900
10. J.M. Esteve, and E. Knecht Mechanisms of autophagy and apoptosis: recent developments in breast cancer cells World J Biol Chem 2 2011 232 238
11. D. Gozuacik, and A. Kimchi Autophagy as a cell death and tumor suppressor mechanism Oncogene 23 2004 2891 2906
12. A. Stein, and D. Arnold Oxaliplatin: a review of approved uses Expert Opin Pharmacother 13 2012 125 137
13. D. Arango, A.J. Wilson, Q. Shi, G.A. Corner, M.J. Arañes, and C. Nicholas et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells Br J Cancer 91 2004 1931 1946
14. S. Nannizzi, G.J. Veal, E. Giovannetti, V. Mey, S. Ricciardi, and C.J. Ottley et al. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines Cancer Chemother Pharmacol 66 2010 547 558
15. S. Goyle, and A. Maraveyas Chemotherapy for colorectal cancer Dig Surg 22 2005 401 414
16. T. André, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, and T. Hickish et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
17. E. Van Cutsem, B. Nordlinger, A. Cervantes ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment Ann Oncol 21 Supplement 5 2010 v93 v97
18. S.V. Rajkumar, P.G. Richardson, T. Hideshima, and K.C. Anderson Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 3 2005 630 639
19. D. Selimovic, B.B. Porzig, A. El-Khattouti, H.E. Badura, M. Ahmad, and F. Ghanjati et al. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells Cell Signal 25 2013 308 318
20. P.G. Richardson, C. Mitsiades, T. Hideshima, and K.C. Anderson Bortezomib: proteasome inhibition as an effective anticancer therapy Annu Rev Med 57 2006 33 47
21. K.S. Suh, and A. Goy Bortezomib in mantle cell lymphoma Future Oncol 2 2008 149 168
22. L. Jia, G. Gopinathan, J.T. Sukumar, and J.G. Gribben Blocking autophagy prevents bortezomib-induced NF-(B activation by reducing I-(Bα degradation in lymphoma cells PLoS One 7 2012 e32584
23. D.S. Hill, S. Martin, J.L. Armstrong, R. Flockhart, J.J. Tonison, and D.G. Simpson et al. Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma Clin Cancer Res 15 2009 1192 1198
24. X. Song, S.Y. Kim, and Y.J. Lee Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells PLoS One 8 2013 e73654
25. X. Song, S.Y. Kim, and Y.J. Lee The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer Mol Cancer Res 10 2012 1567 1579
26. J. Yoo, and Y.J. Lee Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells J Cell Biochem 103 2008 98 109
27. M. Labussiere, S. Pinel, S. Delfortrie, F. Plenat, and P. Chastagner Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts Oncol Rep 20 2008 1283 1287
28. R.A. Campbell, E. Sanchez, J. Steinberg, D. Shalitin, Z.W. Li, and H. Chen et al. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib Eur J Haematol 84 2010 201 211
29. M. Upreti, E.N. Galitovskaya, R. Chu, A.J. Tackett, A.J. Terrano, and D.T. Terrano et al. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance J Biol Chem 283 2008 35517 35525
30. C. Gordy, and Y.W. He The crosstalk between autophagy and apoptosis: where does this lead Protein Cell 3 2012 17 27
31. F. Zhou, Y. Yang, and D. Xing Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis FEBS J 278 2011 403 413
32. A. Oberstein, P.D. Jeffrey, and Y. Shi Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein J Biol Chem 282 2007 13123 13132
33. E. Itakura, C. Kishi, K. Inoue, and N. Mizushima Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG Mol Biol Cell 19 2008 5360 5372
34. R. Kang, H.J. Zeh, M.T. Lotze, and D. Tang The Beclin 1 network regulates autophagy and apoptosis Cell Death Differ 18 2011 571 580
35. S. Sinha, and B. Levine The autophagy effector Beclin 1: a novel BH3-only protein Oncogene 27 2008 S137 S148
36. A. Kihara, Y. Kabeya, Y. Ohsumi, and T. Yoshimori Beclin- phosphatidylinositol 3-kinase complex functions at the trans-Golgi network EMBO Rep 2 2001 330 335
37. E. Wirawan, L. Vande Walle, K. Kersse, S. Cornelis, S. Claerhout, and I. Vanoverberghe et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria Cell Death Dis 1 2010 e18
38. H. Li, P. Wang, Q. Sun, W.X. Ding, X.M. Yin, and R.W. Sobol et al. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1 Cancer Res 71 2011 3625 3634
39. J.A. Ubersax, and J.E. Ferrell Jr. Mechanisms of specificity in protein phosphorylation Nat Rev Mol Cell Biol 8 2007 530 541
40. A. Basu, and S. Haldar Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis FEBS Lett 538 2003 41 47
41. S. Kharbanda, S. Saxena, K. Yoshida, P. Pandey, M. Kaneki, and Q. Wang et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage J Biol Chem 275 2000 322 327
42. Y. Wei, S. Sinha, and B. Levine Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation Autophagy 4 2008 949 951
43. W. He, Q. Wang, B. Srinivasan, J. Xu, M.T. Padilla, and Z. Li et al. JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy Oncogene 2013 1 10
44. Y. Wei, S. Pattingre, S. Sinha, M. Bassik, and B. Levine JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy Mol Cell 30 2008 678 688
45. E. Zalckvar, H. Berissi, M. Eisenstein, and A. Kimchi Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL Autophagy 5 2009 720 722
46. E. Zalckvar, H. Berissi, L. Mizrachy, Y. Idelchuk, I. Koren, and M. Eisenstein et al. DAP-kinase-mediated phosphorylation on the BH3 domain of Beclin 1 promotes dissociation of Beclin 1 from Bcl-XL and induction of autophagy EMBO Rep 10 2009 285 292
47. G.M. Fimia, A. Stoykova, A. Romagnoli, L. Giunta, S. Di Bartolomeo, and R. Nardacci et al. Ambra1 regulates autophagy and development of the nervous system Nature 447 2007 1121 1125
48. C. Liang, P. Feng, B. Ku, I. Dotan, D. Canaani, and B.H. Oh et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG Nat Cell Biol 8 2006 688 699
49. N. Furuya, J. Yu, M. Byfield, S. Pattingre, and B. Levine The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function Autophagy 1 2005 46 52
50. Q. Sun, W. Fan, K. Chen, X. Ding, S. Chen, and Q. Zhong Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase PNAS 105 2008 19211 19216
51. D. Zhai, C. Jin, A.C. Satterthwait, and J.C. Reed Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins Cell Death Differ 13 2006 1419 1421